Freedom Day Solutions, LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
8401 WESTVIEW DRIVE HOUSTON, TX 77055
As of the latest 13F report, the guru’s equity portfolio contained 105 stocks valued at a total of $200.00Mil. The top holdings were MBOX(24.11%), AAPL(3.02%), and SPTM(2.47%).
According to GuruFocus data, these were Freedom Day Solutions, LLC’s top five trades of the quarter.
Freedom Day Dividend ETF
During the quarter, Freedom Day Solutions, LLC bought 250,422 shares of ARCA:MBOX for a total holding of 1,908,238. The trade had a 3.16% impact on the equity portfolio. During the quarter, the stock traded for an average price of $25.04.
On 02/08/2023, Freedom Day Dividend ETF traded for a price of $26.06 per share and a market cap of $59.94Mil. The stock has returned 1.64% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, Freedom Day Dividend ETF has a price-earnings ratio of 14.16 and a price-book ratio of 3.41.
Zoetis Inc
The guru sold out of their 19,658-share investment in NYSE:ZTS. Previously, the stock had a 1.58% weight in the equity portfolio. Shares traded for an average price of $147.98 during the quarter.
On 02/08/2023, Zoetis Inc traded for a price of $163.8 per share and a market cap of $76.34Bil. The stock has returned -17.69% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Zoetis Inc has a price-earnings ratio of 37.40, a price-book ratio of 16.38, a price-earnings-to-growth (PEG) ratio of 2.62, a EV-to-Ebitda ratio of 25.03 and a price-sales ratio of 9.62.
The price-to-GF Value ratio is 0.83, earning the stock a GF Value rank of 9.
AutoZone Inc
The guru established a new position worth 794 shares in NYSE:AZO, giving the stock a 0.98% weight in the equity portfolio. Shares traded for an average price of $2416.82 during the quarter.
On 02/08/2023, AutoZone Inc traded for a price of $2423.77 per share and a market cap of $45.48Bil. The stock has returned 20.40% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, AutoZone Inc has a price-earnings ratio of 20.32, a price-earnings-to-growth (PEG) ratio of 1.11, a EV-to-Ebitda ratio of 14.78 and a price-sales ratio of 2.94.
The price-to-GF Value ratio is 1.10, earning the stock a GF Value rank of 5.
Pool Corp
The guru sold out of their 5,167-share investment in NAS:POOL. Previously, the stock had a 0.89% weight in the equity portfolio. Shares traded for an average price of $316.74 during the quarter.
On 02/08/2023, Pool Corp traded for a price of $386.91 per share and a market cap of $15.11Bil. The stock has returned -13.36% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Pool Corp has a price-earnings ratio of 19.87, a price-book ratio of 12.69, a price-earnings-to-growth (PEG) ratio of 0.82, a EV-to-Ebitda ratio of 15.60 and a price-sales ratio of 2.51.
The price-to-GF Value ratio is 0.66, earning the stock a GF Value rank of 10.
Regeneron Pharmaceuticals Inc
The guru established a new position worth 2,088 shares in NAS:REGN, giving the stock a 0.75% weight in the equity portfolio. Shares traded for an average price of $737.86 during the quarter.
On 02/08/2023, Regeneron Pharmaceuticals Inc traded for a price of $763.0700000000001 per share and a market cap of $83.42Bil. The stock has returned 23.30% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Regeneron Pharmaceuticals Inc has a price-earnings ratio of 27.51, a price-book ratio of 3.66, a price-earnings-to-growth (PEG) ratio of 0.71, a EV-to-Ebitda ratio of 15.37 and a price-sales ratio of 7.03.
The price-to-GF Value ratio is 1.09, earning the stock a GF Value rank of 3.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
